Information Provided By: 
Fly News Breaks for February 26, 2020
MNTA
Feb 26, 2020 | 10:38 EDT
Piper Sandler analyst Danielle Brill says Momenta Pharmaceuticals remains a top pick following the company's Q4 results and update. Updated M254 results are expected at a medical meeting in Q2 and should be an important driver for the stock, Brill tells investors in a research note. If the data consistently show M254 is significantly more potent than intravenous immunoglobulin, "this program could be a game changer," says the analyst. She keeps an Overweight rating on Momenta shares with a $45 price target.
News For MNTA From the Last 2 Days
There are no results for your query MNTA
